Calliditas Therapeutics AB
Industry
- Biotechnology
- Pharmaceuticals
- Vaccines
- Specialty Pharmaceuticals
Other Names/Subsidiaries
- Calliditas Therapeutics Suisse
- Genkyotex
- Pharmalink AB
Latest on Calliditas Therapeutics AB
Although Novartis’s immunoglobulin A nephropathy (IgAN) franchise will face considerable competition from other firms, the accelerated approval in the US of Vanrafia (atrasentan) further solidifies it
Biotech valuations and funding availability went into reverse in the second half of 2021, following a period of abundant financing. Meanwhile, big pharma companies face their own problems, with many b
In the space of only a few years, immunoglobulin A nephropathy (IgAN) has gone from no drug therapies available to three options on a list that is growing. The questions that remain now are how to seg
Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Kaken Obtains Aadi’s Fyarro, Comm